Pliant Therapeutics, Inc.
US ˙ NasdaqGS ˙ US7291391057

SecurityPLRX / Pliant Therapeutics, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership10,966 shares
Latest Disclosed Value $ 13,817
Qube Research & Technologies Ltd reports 28.91% decrease in ownership of PLRX / Pliant Therapeutics, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 10,966 shares of Pliant Therapeutics, Inc. (US:PLRX) valued at $13,817 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 15,425 shares of Pliant Therapeutics, Inc.. This represents a change in shares of -28.91% during the quarter. The current value of the position is $12,940 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F PLIANT THERAPEUTICS COM 729139105 10,966 -4,459 -28.91 14 -27.78 0.0000
2026-02-17 2025-12-31 13F PLIANT THERAPEUTICS COM 729139105 15,425 -34,090 -68.85 19 -75.34 0.0000
2025-11-14 2025-09-30 13F PLIANT THERAPEUTICS COM 729139105 49,515 -102,147 -67.35 73 -58.29 0.0001
2025-08-14 2025-06-30 13F PLIANT THERAPEUTICS COM 729139105 151,662 151,662 176 0.0002
2023-11-13 2023-09-30 13F PLIANT THERAPEUTICS COM 729139105 0 -74,025 -100.00 0 -100.00
2023-08-14 2023-06-30 13F PLIANT THERAPEUTICS COM 729139105 74,025 -101,850 -57.91 1,341 -71.33 0.0049
2023-05-15 2023-03-31 13F PLIANT THERAPEUTICS COM 729139105 175,875 98,805 128.20 4,678 214.17 0.0201
2023-02-14 2022-12-31 13F PLIANT THERAPEUTICS COM 729139105 77,070 50,169 186.49 1,490 164.95 0.0080
2022-11-14 2022-09-30 13F PLIANT THERAPEUTICS COM 729139105 26,901 13,442 99.87 562 420.37 0.0033
2022-08-15 2022-06-30 13F PLIANT THERAPEUTICS COM 729139105 13,459 13,459 108 0.0008
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.